1-5 of 5
Moritz Fürstenau, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Free
Julia Von Tresckow, Paula Cramer, Nisha De Silva, MBBS, MRCP, FRCPath, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Petra Langerbeins, MD, Anna- Maria Fink, MD, Othman Al-Sawaf, MD, Moritz Fürstenau, MD, Thomas Illmer, MD, Holger Klaproth, Eugen Tausch, Matthias Ritgen, Kirsten Fischer, MD, Clemens-Martin Wendtner, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Sebastian Böttcher, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3046.
https://doi.org/10.1182/blood-2019-125895
Published: 2019
Journal Articles

Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group

Free
Anna Maria Fink, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Nadine Kutsch, MD, Moritz Fürstenau, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Michael Kneba, MD PhD, Eugen Tausch, Stephan Stilgenbauer, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Kirsten Fischer, MD, Michael Hallek, MD, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3040.
https://doi.org/10.1182/blood-2019-125063
Published: 2019
Journal Articles

Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG)

Free
Moritz Fürstenau, MD, Georg Hopfinger, MD, Sandra Robrecht, PhD, Anna-Maria Fink, MD, Othman Al-Sawaf, MD, Petra Langerbeins, MD, Paula Cramer, Julia Von Tresckow, MD, Christian Maurer, MD, Nadine Kutsch, MD, Manuela Hoechstetter, MD, Martin Dreyling, MD PhD, Elisabeth Lange, Michael Kneba, Stephan Stilgenbauer, MD PhD, Hartmut Döhner, MD, Manfred Hensel, MD, Michael G. Kiehl, MD PhD, Ulrich Jaeger, MD, Clemens-Martin Wendtner, Valentin Goede, MD, Kirsten Fischer, MD, Michael Hallek, Barbara Eichhorst, Sebastian Theurich, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4429.
https://doi.org/10.1182/blood-2018-99-113257
Published: 2018
Journal Articles

Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL)

Free
Moritz Fürstenau, MD, Jasmin Bahlo, PhD, Anna-Maria Fink, MD, Elisabeth Lange, Peter Dreger, MD, Martin Dreyling, MD PhD, Georg Hess, Matthias Ritgen, MD, Michael Kneba, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD, Clemens-Martin Wendtner, Valentin Goede, MD, Kirsten Fischer, MD, Sebastian Böttcher, Michael Hallek, Barbara Eichhorst
Journal: Blood
Blood (2018) 132 (Supplement 1): 4430.
https://doi.org/10.1182/blood-2018-99-113280
Published: 2018
Journal Articles

Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation)

Free
Paula Cramer, Julia von Tresckow, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Eugen Tausch, MD, Moritz Fürstenau, MD, Petra Langerbeins, MD, Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Kneba, Stephan Stilgenbauer, MD PhD, Michael Hallek
Journal: Blood
Blood (2018) 132 (Supplement 1): 694.
https://doi.org/10.1182/blood-2018-99-113155
Published: 2018